期刊
SEMINARS IN NUCLEAR MEDICINE
卷 37, 期 6, 页码 420-428出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.semnuclmed.2007.07.003
关键词
-
资金
- NCI NIH HHS [CA108620] Funding Source: Medline
The choline transporter and choline kinase enzyme frequently are overexpressed in malignancy. Therefore, positron-emitter-labeled compounds derived from choline have the potential to serve as oncologic probes for positron emission tomography. The fluorine-18 (F-18)-labeled choline derivative fluorocholine (FCH) in particular has demonstrated potential utility for imaging of a variety of neoplasms, including those of the breast, prostate, liver, and brain. The pharmacokinetics of FCH and other choline tracers allow for whole-body imaging within minutes of injection while still achieving high tumor-to-background contrast in most organs, including the brain. These features, along with the possibility of imaging malignancies that have proved elusive with the use of F-18-fluorodeoxyglucose positron emission tomography support further clinical investigations of F-18-labeled choline tracers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据